These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 8795595

  • 1. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
    Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G, Bozzao L, Fieschi C.
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):251-8. PubMed ID: 8795595
    [Abstract] [Full Text] [Related]

  • 2. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
    Gasperini C, Pozzilli C, Bastianello S, Giugni E, Horsfield MA, Koudriavtseva T, Galgani S, Paolillo A, Haggiag S, Millefiorini E, Fieschi C.
    J Neurol Neurosurg Psychiatry; 1999 Nov; 67(5):579-84. PubMed ID: 10519861
    [Abstract] [Full Text] [Related]

  • 3. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [Abstract] [Full Text] [Related]

  • 4. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E, Sloan R, Andersson PB, Goodkin D.
    Rev Neurol (Paris); 1999 Apr; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [Abstract] [Full Text] [Related]

  • 5. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
    De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F.
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
    [Abstract] [Full Text] [Related]

  • 7. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.
    Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Galgani S, Millefiorini E, Paolillo A, Horsfield MA, Bozzao L, Fieschi C.
    Neurology; 1998 Feb; 50(2):403-6. PubMed ID: 9484362
    [Abstract] [Full Text] [Related]

  • 8. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
    Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A, European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group.
    Mult Scler; 2003 Aug; 9(4):342-8. PubMed ID: 12926838
    [Abstract] [Full Text] [Related]

  • 9. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
    Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S.
    Neurology; 2000 May 09; 54(9):1741-5. PubMed ID: 10802778
    [Abstract] [Full Text] [Related]

  • 10. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov 07; 352(9139):1498-504. PubMed ID: 9820297
    [Abstract] [Full Text] [Related]

  • 11. Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients.
    Rovaris M, Capra R, Martinelli V, Gasperini C, Prandini F, Pozzilli C, Comi G, Filippi M.
    J Neurol Sci; 1999 Dec 15; 171(2):130-4. PubMed ID: 10581379
    [Abstract] [Full Text] [Related]

  • 12. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 15; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 13. Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.
    Koudriavtseva T, Pozzilli C, Fiorelli M, Gasperini C, Bagnato F, Galgani S, Frontoni M, Ciccarelli O, Bastianello S.
    Mult Scler; 1998 Oct 15; 4(5):403-7. PubMed ID: 9839299
    [Abstract] [Full Text] [Related]

  • 14. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL, Calabresi PA, Kieseier BC, Liu S, You X, Fiore D, Hung S.
    BMC Neurol; 2017 Feb 10; 17(1):29. PubMed ID: 28183276
    [Abstract] [Full Text] [Related]

  • 15. Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.
    Paolillo A, Bastianello S, Frontoni M, Gasperini C, Giugni E, Ciccarelli O, Luccichenti G, Cannoni S, Pozzilli C.
    J Neurol; 1999 Jun 10; 246(6):443-8. PubMed ID: 10431768
    [Abstract] [Full Text] [Related]

  • 16. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.
    Li DK, Paty DW.
    Ann Neurol; 1999 Aug 10; 46(2):197-206. PubMed ID: 10443885
    [Abstract] [Full Text] [Related]

  • 17. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 10; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

  • 18. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.
    CHAMPS Study Group.
    Am J Ophthalmol; 2001 Oct 10; 132(4):463-71. PubMed ID: 11589865
    [Abstract] [Full Text] [Related]

  • 19. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, Valk J, Hommes OR.
    AJR Am J Roentgenol; 1992 Nov 10; 159(5):1041-7. PubMed ID: 1414773
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH.
    J Neuroimmunol; 1999 Jan 01; 93(1-2):8-14. PubMed ID: 10378864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.